Skip to main content
RCUS
NYSE Life Sciences

Arcus Posts $9M Q3 Revenue, $694M Cash and Sets Multiple Casdatifan Milestones for Q4

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$19.31
Mkt Cap
$2.735B
52W Low
$17.43
52W High
$31.735
52W Position info
11% above low
Off High info
39% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RCUS is trading near its 52-week low of $17.43 (11% above the low).

Summary

Third-quarter revenue fell to $9 million from $26 million a year ago as Gilead collaboration work winds down, while net loss narrowed to $128 million from $135 million on lower R&D ($117 million vs $141 million) and G&A ($23 million vs $27 million), a loss of $1.00 per share. Cash and marketable securities stood at $694 million at September 30; management says that plus $288 million in gross October equity proceeds funds operations into 2029. Full-year 2026 revenue is guided to $70 million-$75 million. The pipeline calendar is the actionable part: PEAK-20, the first-line Phase 3 of casdatifan plus ipilimumab and nivolumab, starts in Q4 2026, PEAK-1 second-line enrollment completes within two to three months, a randomized late-line ARC-20 cohort begins in Q4 2026, and the PRISM-1 interim analysis for quemliclustat in pancreatic cancer is due in Q4 2026. Those readouts and trial starts are what will drive the stock from here, with the cash position removing near-term financing risk.

At the time of this announcement, RCUS was trading at $19.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $17.43 to $31.74. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

RCUS - Latest Insights

RCUS
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.31
Real-time Price: $19.31 info
Change: $0 (0%) info
Market Cap: $2.735B info
RCUS
Oct 21, 2026, 10:53 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.03
Real-time Price: $19.31 info
Change: +$1.28 (+7%) info
Market Cap: $2.735B info
RCUS
Oct 21, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $18.75
Real-time Price: $19.31 info
Change: +$0.560 (+3%) info
Market Cap: $2.735B info
RCUS
Oct 21, 2026, 4:22 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.01
Real-time Price: $19.31 info
Change: +$0.2962 (+2%) info
Market Cap: $2.735B info
RCUS
Oct 20, 2026, 12:16 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $24.00
Real-time Price: $19.31 info
Change: -$4.69 (-20%) info
Market Cap: $2.735B info